BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours

被引：18

作者：

Mackensen, A. ^{[1
]}

Haanen, J. B. A. G. ^{[2
]}

Koenecke, C. ^{[3
]}

Alsdorf, W. ^{[4
]}

Wagner-Drouet, E. ^{[5
]}

Heudobler, D. ^{[6
]}

Borchmann, P. ^{[7
]}

Bokemeyer, C. ^{[4
]}

Klobuch, S. ^{[2
]}

Smit, E. ^{[2
]}

Mueller, F. ^{[8
]}

Desuki, A. ^{[5
]}

Lueke, F. ^{[6
]}

Wiegert, E. ^{[9
]}

Flemmig, C. ^{[10
]}

Schulz-Eying, C. ^{[10
]}

Rengstl, B. ^{[10
]}

Preussner, L. ^{[10
]}

Tuereci, Ö. ^{[10
]}

Sahin, U. ^{[10
]}

机构：

[1] Univ Hosp Erlangen, Dept Med Hematol Oncol 5, Erlangen, Germany

[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands

[3] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[4] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Div Pneumol, Hamburg, Germany

[5] Univ Med Ctr Mainz, Med Dept Hematol Oncol & Pneumol 3, Mainz, Germany

[6] Univ Hosp Regensburg, Dept Internal Med Haematol & Oncol 3, Regensburg, Germany

[7] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[8] Univ Hosp Erlangen, Dept Internal Med Hematol Oncol 5, Erlangen, Germany

[9] Bexon Clin Consulting, Mem Stn, Montclair, NJ USA

[10] BioNTech SE, BioNTech Cell Gene Therapies, Mainz, Germany

来源：

关键词：

D O I：

10.1016/j.annonc.2022.08.035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA38

引用

页码：S1404 / S1405

页数：2